First-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid malignancies.

Abstract

In this Phase 1 portion of a first-in-human Phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics, and pharmacodynamics. Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety. Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks using an accelerated titration design followed by a traditional 3+3 design, with an initial dose level of 2 mg. Twenty-eight participants were enrolled across 7 cohorts and received a median of 4 cycles of 23ME-00610. No treatment-related serious adverse events were observed, and the maximum tolerated dose (MTD) was not reached. Overall, the PK of 23ME-00610 was linear and dose proportional at doses ≥ 60 mg, with a median terminal half-life of 13 days at 1400 mg. Peripheral saturation of CD200R1 was observed for doses ≥ 60 mg. Immune-related AEs, including rash, pruritus, and hypothyroidism, were predicted by phenome-wide association studies and observed for doses ≥ 60 mg. A confirmed partial response (PR) was observed in a participant with well-differentiated pancreatic neuroendocrine cancer whose tumor was among those with the highest tumor CD200 expression. 23ME-00610 has mild-to-moderate on-target adverse events and PK/PD consistent with tumor target saturation and dosing Q3W. The trend for clinical benefit in participants with tumor CD200 expression suggests 23ME-00610 inhibits CD200R1 signaling and may reverse CD200-mediated immune evasion. Based on PK/PD, safety, and preliminary anti-tumor activity, 1400 mg Q3W was selected as the dose for further study.